Chief executive of Priovant Therapeutics
Appears in 1 story
Leading Lisraya's US launch
The FDA approved Lisraya on August 27, 2026, clearing the first targeted therapy ever approved for dermatomyositis, a rare autoimmune disease that inflames skin and weakens muscles. The once-daily pill showed gains in skin disease, muscle strength, and physical function within four weeks.
Updated Aug 28
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
